OPDP Focuses on Misleading Opioid Claims Amid National Crisis

OPDP Focuses on Misleading Opioid Claims Amid National Crisis

Amid a surge in opioid overdose deaths over the past year, the FDA’s Office of Prescription Drug Promotion (OPDP) has asserted the agency’s “ongoing commitment to combat inappropriate opioid use”...

 

February 23, 2021 9:02 AM

Maryland Sued Over Digital Ad Tax

Maryland Sued Over Digital Ad Tax

On Feb. 18, four trade groups whose members include tech giants Amazon, Facebook and Google – filed a lawsuit stating that Maryland’s new digital ad tax law “is illegal in myriad ways and should be declared unlawful”...

February 19, 2021 4:39 PM

Maryland Legislature Overrides Gov. Hogan Veto, Enacts Digital Advertising Tax

Maryland Legislature Overrides Gov. Hogan Veto, Enacts Digital Advertising Tax

The Maryland House and Senate voted last week to override Gov. Larry Hogan’s May 2020 veto and enact the nation’s first tax on digital advertising, a move that other states are in the process of considering...

February 15, 2021 2:40 PM

FDA Plans Expedited Approval Path for Modified COVID-19 Vaccines

FDA Plans Expedited Approval Path for Modified COVID-19 Vaccines

With growing concern about the spread of new COVID-19 variants, companies developing vaccine modifications will not have to “start at square one,” according to FDA Acting Commissioner Janet Woodcock, M.D...

February 8, 2021 2:47 PM

Upcoming Event

12/16/20 Webinar: What’s next for the FDA in the Biden administration?

Dec. 16, 2020, 12-1 pm ET

The FDA entered 2020 with a new Commissioner, then soon faced unusual scientific challenges—and unprecedented political attacks—as it worked to cope with the COVID-19 pandemic. Yet, even as its credibility took some hits, the FDA has moved forward aggressively to establish a streamlined process for evaluating COVID-19 vaccines and drugs, and is on track to approve a high number of new molecular entities for other indications.

What’s next for the FDA under a Biden administration? Join us for the insights of Nancy Bradish Myers, president of Catalyst Healthcare Consulting and former Senior Strategic Advisor in the FDA Commissioner’s office. Who will be the next Commissioner, and what will his or her priorities be? Where will the agency fit in the Biden’s plans to combat COVID-19? What can the FDA do to rebuild its credibility? What lessons does the pandemic hold for the drug approval process? What will be in the next PDUFA legislation?

  • Webinar: Wednesday, Dec. 16, 12-1 pm Eastern time
  • Faculty: Nancy Bradish Myers, president, Catalyst Healthcare Consulting
  • Zoom link to be provided to registrants
  • Tuition: Only $75 (from member companies) or $90 (from non-member companies)
  • If uncertain on membership, please see our list of member companies.
  • Online registration open now—see below.

Don’t miss this inside look at an agency with profound impact on our industry!

For further information, contact jbigelow@cohealthcom.org.

 

 

 

Read More +

About Us

CHC

CHC

The Coalition for Healthcare Communication is an organization that promotes the free exchange of scientific and medical information. It is essential that healthcare professionals and the general public receive truthful, accurate information regarding pharmaceuticals, medical products and devices, and patient care.

In addition to white papers and other documents published by the Coalition, you can also find relevant information on current healthcare and health economics issues, as well as policy positions published by government agencies and other professional organizations.